SUMMARY The effect of i.v. nitroglycerin administration on indexes of infarct size was examined in 31 patients with acute myocardial infarction. Serial creatine kinase (CK) and CK-MB isoenzyme determinations were used to calculate infarct size. Twenty-nine patients served as controls. Two subgroups of the study group were formed to evaluate differences between early and late intervention. In the first group (n = 22), continuous infusion of nitroglycerin over 48 hours was initiated within 8 hours (mean 4.5 hours) after the onset of symptoms. Peak CK activity for the nitroglycerin-treated patients (n = 9) in this subgroup was 544 U/1 vs 871 U/1 for the controls (n = 13) (p < 0.05). The rate of CK release was reduced from 79 to 33 U/1.hr (58%), as was total CK and CK-MB release (p < 0.02 (fig. 3) .
THE BENEFICIAL EFFECTS of i.v. nitroglycerin in acute myocardial infarction have been documented.'-4 Left ventricular filling pressure declines significantly, reducing preload. Cardiac output increases slightly and blood pressure decreases, reducing afterload. As a result, myocardial oxygen demand is diminished.5' Several authors have reported a reduction of myocardial ischemia3 -1 in response to nitroglycerin, suggesting that the agent may minimize the ischemic border zone and reduce final infarct size.
Infarct size cannot be determined directly. However, measurement of the activity of creatine kinase (CK) and its CK-MB isQenzyme provides an indirect index of myocardial necrosis. In the present study, 60 patients were assigned randomly to a nitroglycerin or control group. In 21 cases, the study could be initiated within 8 hours after the onset of symptoms.
artery via a brachial vein. Systolic, diastolic and mean pulmonary arterial and capillary wedge pressures, as well as right arterial pressure, were measured. Cardiac output was determined by both the thermodilution technique12 and the Fick principle (measurement of arteriovenous oxygen difference, hemoglobin and oxygen consumption). Blood pressure was taken with a cuff sphygmomanometer and stethoscope. Coronary perfusion pressure was calculated by subtracting diastolic pulmonary arterial pressure from mean arterial pressure. Values were obtained before nitroglycerin administration and thereafter at 4-hour intervals over 2 days.
Enzyme Activity Determinations CK activity curves were recorded in all patients during the first 48 hours and longer in patients with persistently high values. In 50 patients, the CK isoenzyme CK-MB was also determined. For both enzyme calculations, blood was drawn hourly during the first 12 hours and subsequently at 3-hour intervals. A commercial test kit (Merck t test8' 14) was used. Peak CK and CK-MB enzyme activity values (CK max and CK-MB max) were determined from individual activity curves. The beginning of enzyme activity increase is expressed as 0 hour. Thereafter, enzyme values were calculated every 6 hours to establish mean CK and CK-MB curves ( fig. 3) .
The f^ollowing additional measurements were determined using a computer program developed by Shell et al. '5 16 (1) Individual appearance curves of CK and CK-MB, including the quantity of enzymes normally lost through excretion, were standardized to 0 hour.
(2) The rate of CK and CK-MB release was calculated as 90% of total appearance divided by the time to 90% appearance (U/l.hr17). 
CK and CK-MB Activity Curves
Nitroglycerin was given a mean of 1.1 hours after the increase of CK values. Enzyme activities increased sharply in control patients, while in the nitroglycerin group the rate of increase was markedly slower and a lower plateau was reached. Thereafter, the slopes of both curves were parallel. A significant difference in enzyme activities between the groups was seen at 6 and 12 hours ( fig. 3 ).
CK and CK-MB Appearance Curves CK and CK-MB appearance curves of individual patients were flatter and reached a lower plateau in the treated group (fig. 4) . By careful randomization of patients into treatment and control groups, both populations proved to be comparable as to age, time from onset of infarction, localization and enzyme levels at admission. Initial hemodynamic measurements, such as heart rate, left ventricular filling pressure, cardiac output and blood pressure, were similar, ruling out an accidental selection bias (table 1) .
The need for medication with various cardiotropic drugs was greatly reduced in the treated patients. Anginal pain, left ventricular failure, and ventricular ectopic beats were less frequent with concomitantly lower requirements of morphine, furosemide and lidocaine, respectively (table 1 ). This appears to be related to the beneficial effect of nitroglycerin on myocardial ischemia and reduction of infarct size.
The combined results of the early and late intervention groups indicate that significant reductions in peak CK and CK-MB values result from nitroglycerin treatment. CK and CK-MB infarct size are reduced as well. Infarct size in terms of CK-MB gEq differs more from control than CK gEq. This is true for the combined as well as individual early and late intervention subgroups. In gEq, the CK-MB isoenzyme appears to demonstrate better the difference between the treatment and control groups. The discrepancy between CK and CK-MB suggests that the latter is a more specific indicator of myocardial necrosis. This inconsistency, however, cannot be explained with certainty, although it should be noted that peak CK and CK-MB values correspond more closely to one another.
One should attempt to avoid any delay in initiating therapy. The value of early intervention has been documented in a recent experimental study. In animal studies, Rasmussen et al. 36 found a 50% reduction in necrosis when propranolol was given before the onset of myocardial infarction. When treatment was initiated 3 hours after infarction, the reduction was only 30%, and after 6 hours no reduction was observed.
Similar findings were reported in clinical studies by Peter et al.,'7 who found necrosis reduced when propranolol was given within the first 4 hours after infarction.
The reduction in infarct size as indicated by CK and CK-MB analysis was similar in the early and late intervention group. Even in late intervention, peak enzyme values were lower with nitroglycerin. When therapy was begun, CK and CK-MB values decreased considerably in the treated group, while elevated values in control patients remained unchanged. This response may be because in humans, but not in the experimental animal, myocardial infarction is an ongoing process. Bleifeld et al.80 produced evidence supporting this hypothesis. In some patients,fslow onset of infarction and a prolonged course was evident from the CK activity curves. Clinical symptoms with reinfarction and extension of the primary infarct are possible in humans.37 Thus, there is some evidence of differences between experimentally induced and human myocardial infarction. The period during which infarct size may be influenced thus appears to be longer in humans than in experimental animals.
Periodic hemodynamic monitoring revealed characteristic findings. Nitroglycerin primarily reduced left ventricular filling pressure, and thus, preload. Decreased diastolic wall tension increases endocardial perfusion. Blood pressure decreased, but not extensively. The reduction of systemic vascular resistance, left ventricular filling pressure, and infarct size may account for the increased cardiac output in treated patients. Furthermore, the drug seems to stabilize coronary perfusion pressure to some extent. The decrease of preload and afterload indicates decreased oxygen demand and may explain the beneficial effects on myocardial ischemia.
In summary, nitroglycerin significantly reduced serum CK and CK-MB enzyme activity. It is beneficial if given within 8 hours after onset of symptoms. However, even in the late intervention group, nitroglycerin reduced CK and CK-MB compared with control patients. The infarct size calculated from the serum enzymes was 30% lower in the treated patients. Preliminary results suggest that treatment with nitroglycerin reduces early mortality from myocardial infarction without increasing the risk of late mortality.
